Matthew Klein

“PTC is a global rare disease company that discovers, develops, and commercializes innovative therapies for diseases of high unmet need.”

“Look, I think we're incredibly excited for the company's position today. We're exactly where we want to be, as we planned over the past couple years to really transform the company into the diversified, valuable, rare disease company we believe it could be.”

“You've heard us refer to as $2 billion plus, multi-billion, but everything we're seeing thus far reaffirms our confidence in that. I think the keys to early success were a few.”

“I'm excited to share our outstanding third quarter results. The highlight of the quarter was the initiation of the Sephience global launch in Europe and the United States.”

“I'm pleased to share results from another strong quarter, highlighted by the first approvals for Sephience for the treatment of children and adults with PKU. We expect Sephience to be the foundational product for PTC's sustainable growth and path to profitability.”